iifl-logo

Ishita Drugs & Industries Ltd Board Meeting

80.74
(2.20%)
Jun 2, 2025|01:22:00 PM

Ishita Drugs CORPORATE ACTIONS

02/06/2024calendar-icon
02/06/2025calendar-icon
PurposeBoard Meetings DateAnnouncement Date
Board Meeting30 May 202523 May 2025
Ishita Drugs & Industries Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/05/2025 inter alia to consider and approve 1. The Audited Financial Results of the Company for the quarter and year ended 31st March 2025 pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015. 2. To consider and approve the Directors Report with the Annexure Corporate Governance Report Management Discussion and Analysis Report and Notice for convening the 32nd Annual General Meeting of the Company. 3. To consider the appointment of M/s Meenu Maheshwari & Associates Practicing Company Secretary as the Secretarial Auditor of the Company for the year 2025-26. 4. To consider the re-appointment of Mr. Arvind Sapkal [DIN: 08607096] for the further term of Five years as an Independent Non-Executive Director of the Company. 5. To consider the re-appointment of Internal Auditors of the Company for the year 2025-26. 6. To take on record Disclosure of Interest of Directors. 7. Any other matter with permission of the Chair.
Board Meeting13 Feb 20256 Feb 2025
ISHITA DRUGS & INDUSTRIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/02/2025 inter alia to consider and approve 1. To consider approve and take on record the Unaudited Financial Results of the Company for the quarter ended 31st December 2024. 2. Any other matter with permission of the Chair. Board of Directors of Ishita Drugs and Industries Limited, at its meeting held today i.e.13th February, 2025 have 1. Approved the Unaudited Financial Results of the Company for the quarter and nine months ended 31st December, 2024. and the Limited Review Report issued by the Statutory Auditors of the Company enclosed herewith. Approval of the Unaudited Financial Results of the Company for the quarter ended 31st December, 2024, the limited review report issued by statutory auditor of the company attached herewith. (As Per BSE Announcement Dated on 13.02.2025)
Board Meeting12 Nov 20246 Nov 2024
ISHITA DRUGS & INDUSTRIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/11/2024 inter alia to consider and approve 1.To consider approve and take on record the Unaudited Financial Results of the Company for the quarter ended 30th September 2024. 2.Any other matter with permission of the Chair. Board of Directors of Ishita Drugs and Industries Limited, at its meeting held today i.e. 12th November, 2024 have 1. Approved the Unaudited Financial Results of the Company for the quarter ended 30th September, 2024. The Limited Review Report issued by the Statutory Auditors of the Company enclosed herewith. 2. Acceptance of the Resignation received from Mr. Govind Madanlal Gupta [DIN: 00052690], non-executive independent Director of the Company, due to his pre-occupation and other professional commitments, with effect from close of business hours on 12th November, 2024. Read less.. (As Per BSE Announcement Dated on: 12/11/2024)
Board Meeting13 Aug 20247 Aug 2024
ISHITA DRUGS & INDUSTRIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/08/2024 inter alia to consider and approve 1. To consider approve and take on record the Unaudited Financial Results of the Company for the quarter ended 30th June 2024. 2. Any other matter with permission of the Chair. 1. Board of Directors of our company approved the appointment of Ms. Dhwani Solanki (DIN: 10299290) as as Additional director in the category of non executive independent director for 5 years, subject to the approval of shareholders of the Company. 2. Acceptance of resignation received from Mr. Niranjan Agrawal (DIN: 06503361) as non executive independent director, due to personal reasons with the effect from close of business hours on 13th August, 2024. (As Per Bse Announcement Dated on 13.08.2024)

Ishita Drugs: Related News

No Record Found

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Knowledge Center
Logo

Logo IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000

Logo IIFL Capital Services Support WhatsApp Number
+91 9892691696

Download The App Now

appapp
Loading...

Follow us on

facebooktwitterrssyoutubeinstagramlinkedintelegram

2025, IIFL Capital Services Ltd. All Rights Reserved

ATTENTION INVESTORS

RISK DISCLOSURE ON DERIVATIVES

Copyright © IIFL Capital Services Limited (Formerly known as IIFL Securities Ltd). All rights Reserved.

IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)

ISO certification icon
We are ISO 27001:2013 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.